Clinical trials: IgG4-Related Diseases
IgG4 Related Disease
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
- Trial name
- NCT04540497
- Testing
- Inebilizumab
- Where
- 72 sites in United States, Argentina and 19 more
- Volunteers
- 135 people
- Sponsor
- Amgen
IgG4-RD
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
- Trial name
- NCT02725476
- Testing
- XmAb5871
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Xencor, Inc.
Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
- Conditions
- Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
- Trial name
- NCT01584388
- Testing
- Rituximab
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
IgG4-related Disease
Safety and Efficacy of Abatacept in IgG4-Related Disease
This is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study.
- Trial name
- NCT03669861
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
IgG4 Related Disease
Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
- Trial name
- NCT04602598
- Testing
- Zanubrutinib 80 MG
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Matthew C. Baker
IgG4 Related Disease, IgG4-RD
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.
- Trial name
- NCT04918147
- Testing
- elotuzumab, methylprednisolone, diphenhydramine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)